ARMIDA LABS, INC.
Targeting pancreatic cancer metastases with Targefrin
Targeting pancreatic cancer metastases with Targefrin is a funding opportunity from ARMIDA LABS, INC., up to 1162000, closing August 31, 2027.
Aug 31, 2027
(396d left)Overview
ABSTRACT We intend to devise a novel therapeutic strategy based on a specific cancer cell receptor named EphA2, which is abundant on the surface of metastatic pancreatic cancers and other solid tumors including breast, lung, prostate, ovarian, and renal cancers. Over the past several years our studies focused on…